Human evidence record · Orforglipron
ATTAIN-1: orforglipron for obesity treatment
Mean weight change was -7.5%, -8.4% and -11.2% versus -2.1% with placebo.
Quick read
Human evidence record
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Who was studied?
Adults with obesity without diabetes
How many?
n=3127
What happened?
Mean weight change was -7.5%, -8.4% and -11.2% versus -2.1% with placebo.
What stops us overclaiming?
Trial doses/formulation must not be silently converted into current commercial tablet strengths.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Mean weight change was -7.5%, -8.4% and -11.2% versus -2.1% with placebo.
Study details
Study designMultinational randomized, double-blind, placebo-controlled trial
PhasePhase III
PopulationAdults with obesity without diabetes
Sample size3127
RouteOral
Regimen / exposure6, 12 or 36 mg once daily in the trial formulation
Duration72 weeks
ComparatorPlacebo
Primary endpoint / questionPercent change in body weight
Safety resultGastrointestinal events were most common; discontinuation due to adverse events was higher with orforglipron.
Key limitationsTrial doses/formulation must not be silently converted into current commercial tablet strengths.
Registry / identifierNCT05869903